About: SARS-CoV-2 E protein is a potential ion channel that can Be inhibited by Gliclazide and Memantine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 E protein is a potential ion channel that can Be inhibited by Gliclazide and Memantine Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 E protein is a potential ion channel that can Be inhibited by Gliclazide and Memantine
Creator	Arkin, Isaiah Pratap, Prabhat Tomar, Singh
Source	Elsevier; Medline; PMC
abstract	COVID-19 is one of the most impactful pandemics in recorded history. As such, the identification of inhibitory drugs against its etiological agent, SARS-CoV-2, is of utmost importance, and in particular, repurposing may provide the fastest route to curb the disease. As the first step in this route, we sought to identify an attractive and viable target in the virus for pharmaceutical inhibition. Using three bacteria-based assays that were tested on known viroporins, we demonstrate that one of its essential components, the E protein, is a potential ion channel and, therefore, is an excellent drug target. Channel activity was demonstrated for E proteins in other coronaviruses, providing further emphasis on the importance of this functionally to the virus’ pathogenicity. The results of a screening effort involving a repurposing drug library of ion channel blockers yielded two compounds that inhibit the E protein: Gliclazide and Memantine. In conclusion, as a route to curb viral virulence and abate COVID-19, we point to the E protein of SARS-CoV-2 as an attractive drug target and identify off-label compounds that inhibit it.
has issue date	2020-06-20(xsd:dateTime)
bibo:doi	10.1016/j.bbrc.2020.05.206
bibo:pmid	32828269
has license	no-cc
sha1sum (hex)	abc086df92b05afee2cf530f8e9349276576a452
schema:url	https://doi.org/10.1016/j.bbrc.2020.05.206
resource representing a document's title	SARS-CoV-2 E protein is a potential ion channel that can Be inhibited by Gliclazide and Memantine
has PubMed Central identifier	PMC7305885
has PubMed identifier	32828269
schema:publication	Biochem Biophys Res Commun
resource representing a document's body	covid:abc086df92b05afee2cf530f8e9349276576a452#body_text
is schema:about of	named entity 'provide' named entity 'compounds' named entity 'essential' named entity 'Gliclazide' named entity 'protein' named entity 'protein' named entity 'PROTEIN ' named entity 'IDENTIFY' named entity 'screening' named entity 'attractive' named entity 'curb' named entity 'COVID-19' named entity 'repurposing' named entity 'coronaviruses' named entity 'viral' named entity 'inhibit' named entity 'Journal' named entity 'drug target' named entity 'coronaviruses' named entity 'virus' named entity 'protein' named entity 'Ion Channel' named entity 'Gliclazide' named entity 'SARS-CoV-2' named entity 'Coronaviridae' named entity 'exocytotic' named entity 'virulence' named entity 'protein' named entity 'protein' named entity 'ERGIC' named entity 'infectious bronchitis virus' named entity 'SARS-CoV-2' named entity 'drug targets' named entity 'SARS-CoV-2' named entity 'ion channel' named entity 'Memantine' named entity 'SARS-CoV-2' named entity 'protein' named entity 'Gliclazide' named entity 'growth retardation' named entity 'membrane permeabilization' named entity 'influenza A virus' named entity 'proton motive force' named entity 'vesicles' named entity 'ion channel' named entity 'drug candidate' named entity 'SARS-CoV-2' named entity 'protein' named entity 'protein' named entity 'acidic solution' named entity 'heterologous protein expression' named entity 'infectious bronchitis virus' named entity 'IPTG' named entity 'human coronavirus' named entity 'protein channel' named entity 'protein' named entity 'protein' named entity 'protein channel' named entity 'pathogenicity' named entity 'protein' named entity 'growth retardation' named entity 'bacterial death' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'coronaviruses' named entity 'Golgi intermediate compartment' named entity 'protein' named entity 'structural proteins' named entity 'protein' named entity 'protein' named entity 'coronaviruses' named entity 'protein' named entity 'viral infection' named entity 'Golgi' named entity 'viral pathogenesis' named entity 'hydrophobicity' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'protein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software